Fusemachines has launched a new video series titled "Can the Expert Tell?" to demonstrate the advanced capabilities of its HireFoundry.ai real-time Interview Agent. The series features industry experts challenged to identify whether they are interviewed by a human expert, a specialized recruiter, a generalist recruiter, or a generalist recruiter aided by AI. This showcases how the AI agent enhances recruiters' ability to probe deeply into candidates' competencies during live interviews, blending AI intelligence with human workflows. The initiative highlights Fusemachines' vision of augmenting human recruiters with AI to improve hiring processes without replacing human judgment.
Fusemachines' new video series on HireFoundry.ai's real-time Interview Agent is the subject, with Pluang's Technology sector market data providing context. As of Nov 02, 2026 19:21 WIB, out of 150 priced Technology-sector US stocks tradable on Pluang, 96 rose and 40 fell. Notable movers include STM (STMicroelectronics NV) at USD 48.15 with a 1-day change of +3.02% and a typical hold time of 66 days, AXTI (AXT Inc) at USD 56.68 with +2.93%, and CRDO (Credo Technology Group Holding Ltd) at USD 155.00 with +2.66%.
Callan JMB has received and will install a QuickStrip™ oral thin-film production line from Rapid Dose Therapeutics at its Texas facility, marking a key step in expanding its domestic pharmaceutical manufacturing. This new capability aims to produce f...
Known, a company developing accountability infrastructure for autonomous AI, announced that Edna Conway, former senior security executive at Microsoft and Cisco, has joined its Advisory Council. Conway brings extensive experience in cybersecurity and...
A SEON survey of 2,026 U.S. adults reveals that while 68% use AI agents weekly for personal tasks, half are uncomfortable letting AI handle credit card purchases. Only 15% would share financial info with AI, and 43% lack confidence in spotting fraudu...
Radiopharm Theranostics announced progress in its oncology radiopharmaceutical pipeline, including preparing for a pivotal Phase 3 imaging trial of RAD101 for recurrent brain metastases after a successful FDA End-of-Phase 2 meeting. The company also ...
UroGen Pharma has dosed the first patient in a Phase 1 trial testing UGN-501, a next-generation oncolytic virus for non-muscle invasive bladder cancer (NMIBC). The trial aims to evaluate the safety and tolerability of UGN-501 administered directly in...
